vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
December 02 2019 - 07:30AM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company focused on the development of orally
administered treatments for type 1 diabetes and Alzheimer’s
disease, today announced that it is scheduled to present a general
company update at the 31st Annual Piper Jaffray Healthcare
Conference on Wednesday, December 4, 2019 at 10:50 a.m. Eastern
Time in New York City. Company management will also be meeting with
members of the investment community during one-on-one meetings at
the conference.
A live webcast of the presentation can be
accessed here and will be accessible for 30 days following the
presentation at www.vtvtherapeutics.com.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage
biopharmaceutical company focused on developing oral small molecule
drug candidates. vTv has a pipeline of clinical drug candidates led
by programs for the treatment of type 1 diabetes, Alzheimer’s
disease, and inflammatory disorders. vTv’s development partners are
pursuing additional indications in type 2 diabetes, COPD, and
genetic mitochondrial diseases.
ContactsInvestors: vTv
Therapeutics Inc. IR@vtvtherapeutics.com
or Media:Glenn SilverLazar FINN
Partners646-871-8485gsilver@lazarpartners.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Feb 2024 to Mar 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2023 to Mar 2024